証拠の質 4.63/5
8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。
- D1 出典への根拠
- 5/5
- D2 出典の権威性
- 5/5
- D3 算術
- 4/5
- D4 不確実性
- 4/5
- D5 範囲
- 5/5
- D6 文章
- 4/5
- D7 認識の誠実性
- 5/5
- D8 注意事項の完全性
- 5/5
● あなたの要因 — このリスクをクリック ▾ して表示
- あなたの要因
認知リスク
2型糖尿病は、人々が恐れるもののリストにほとんど現れない。チャップマンのアメリカ人の恐怖調査の最上位層には登場せず、いかなる災害映画の前提にもならず、60歳未満のほとんどの成人はそれを「ライフスタイルの問題」と「薬で管理できるもの」の間のどこかに位置づけている。直感的なモデルでは、糖尿病は緩慢で慢性的であり、ほとんどが不便の問題である——共に生きる病気であって、それで死ぬ病気ではない、と。これは、糖尿病疫学における最大の会計上の問い（死亡の原死因か寄与死因か）を誤った答えへと押しつぶし、ランキングでその上位に位置する心血管および腎臓の死亡を駆動する糖尿病の役割を過小評価している。
概算: 米国成人の31%が、自分自身が糖尿病を経験することについて非常にまたはある程度心配していると答えている
出典: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
実際のリスク
世界全体で年間約6.7 millionの糖尿病関連死（20-79歳の成人）
世界の成人20-79歳、糖尿病関連死（IDF 2021）
計算を表示
見出しの数値として、IDF Diabetes Atlas第10版（2021）の、2021年に世界全体で20-79歳の成人における約6.7 millionの糖尿病関連死という推定値を用いる。これはより広い「糖尿病に帰属可能な」数であり、糖尿病が原死因であった死亡と、糖尿病が心血管または腎臓の死因の主な駆動要因であった死亡を含む。より狭いWHOの「原死因」の数ははるかに小さい——WHO Diabetes fact sheet（2024年更新）によれば、世界全体で年間約1.6 millionの直接的な糖尿病死亡に加え、約530,000の糖尿病に帰属可能な腎疾患死亡、およびすべての心血管死亡の約11%である。GBD 2021糖尿病共同研究者によれば、2型糖尿病は糖尿病症例の約96%と世界の糖尿病疾病負担の約95%を占めるため、全糖尿病の数値は実質的に2型の数値である。約5.5 billion（18歳以上）の世界の成人人口全体で、年間6.7 millionの死亡は成人1,000人あたり年間約1.22である。60年の成人期にわたって素朴に累積すると：1 - (1 - 1.22e-3)^60 ≈ 0.070。糖尿病の死亡が、年ごとのハザードが平均より数倍高い成人期後半に集中しており、素朴な累積が生涯の数値を過小評価することを反映して、0.075（≈13分の1）へとわずかに上方修正した。スコープは米国成人の生涯ではなく世界の成人の生涯である。なぜなら糖尿病の有病率は地域間でおよそ四倍変動し（オセアニア約12%対サブサハラアフリカ約5.5%、年齢標準化）、見出しは米国固有のものではなく世界のベースラインを反映する必要があるからである。
注意事項: このページで最大の不確実性は、「糖尿病に帰属可能な死亡」の定義である。厳格なWHOの原死因の定義では、糖尿病は世界全体で年間約1.6 millionの人々を直接…
このページで最大の不確実性は、「糖尿病に帰属可能な死亡」の定義である。厳格なWHOの原死因の定義では、糖尿病は世界全体で年間約1.6 millionの人々を直接死亡させ、これは生涯の数値を約50分の1に近づける。より広いIDFの糖尿病関連の定義——糖尿病が駆動する心血管および腎臓の死亡を糖尿病に帰する——では、数は年間約6.7 millionであり、生涯の数値は約13分の1に近い。Likelierはより広い数値を見出しとして用いる。なぜなら、それは「糖尿病が殺す」という言葉が日常言語で実際に意味するものと一致するからである。65歳で心臓発作で死ぬ2型糖尿病患者は、意味のある意味で糖尿病で死んだのである。不確実性帯は両方の方法論を含む。2型糖尿病は世界の糖尿病症例の約95%を占める（GBD 2021）ため、「糖尿病」と「2型糖尿病」の数値は、見出しについては実質的に互換である。personal_factor_multipliersは、疫学文献からのオーダー・オブ・マグニチュードの相対リスクであり、較正された個人リスク計算機ではない。正式な個人的推定には、AUSDRISK、FINDRISC、QDiabetesといった臨床ツールが適切な手段である。セマグルチド2.4mgの保護的乗数（0.80）はSELECT試験に由来し、これは確立された心血管疾患を持つが糖尿病を持たない過体重/肥満の成人を登録した。この乗数は、主要な心血管有害事象の約20%の削減（ここでの糖尿病に帰属可能な死亡の主要な構成要素）を反映しており、糖尿病を死因とする死亡の測定された減少ではなく、精密な糖尿病死亡の調整というよりも心血管保護のシグナルとして読まれるべきである。
リスクはどう変わるか
見出しの数値は大きく異なる状況の平均です。シナリオや文脈による確率の違いは以下の通りです:
13分の1 · 7.5%
IDF 6.7M diabetes-related deaths (adults 20-79) compounded over 60 adult years
11分の1 · 9.0%
CDC ~94K underlying-cause + ~300K contributing-cause diabetes deaths per year; ~12% of US adults have diabetes
5.6分の1 · 18%
Several Pacific Island nations have adult diabetes prevalence above 25% (Marshall Islands, Kiribati, Tuvalu, Nauru); GBD 2021 places Oceania regional prevalence at 12.3%, the highest in the world
9.1分の1 · 11%
GBD 2021 age-standardised prevalence 9.3%, second-highest global region; driven by urbanisation and BMI transition
9.1分の1 · 11%
Elevated risk at lower BMI than European-ancestry populations; India and Pakistan together account for a large share of global diabetes cases
25分の1 · 4.0%
Lower prevalence and higher competing mortality (infectious disease, maternal) mask the underlying trend; diabetes mortality is rising fastest here
バーの長さと濃淡は、これらのシナリオを他のリスクとではなく、互いに比較して順位付けしたものです。正確な確率は各項目の横に表示されています。
関連するリスク
似たテーマの他のリスク — 関連する不安を探るために。
比較対象を選択
Type 2 diabetes is probably the single most underrated major killer on this site. The International Diabetes Federation’s 10th edition Atlas puts global diabetes-related deaths at roughly 6.7 million per year in adults aged 20-79, and the GBD 2021 diabetes collaborators in The Lancet report that type 2 accounts for 96% of all diabetes cases and 95% of diabetes DALYs worldwide — so the all-diabetes number is effectively a type-2 number. Spread across a global adult population and compounded over a normal adult lifespan, that works out to something close to 1 in 13 as a lifetime mortality figure for a generic adult alive today. For scale: that is comparable to heart disease, larger than stroke, and several thousand times the lifetime mortality from a plane crash. Diabetes almost never cracks the top tier of anyone’s fear list.
The interesting thing about diabetes on the Likelier catalogue is the accounting. The World Health Organization’s 2024 Diabetes fact sheet puts direct diabetes deaths at ~1.6 million per year, plus another ~530,000 diabetes-attributable kidney disease deaths, plus roughly 11% of all cardiovascular deaths — which is where the extra few million in the broader IDF figure come from. On the strict underlying-cause definition a type 2 diabetic who dies of a heart attack at 65 dies of heart disease; on the broader “diabetes-related” definition that same death is diabetes-attributable, and the two accounting conventions disagree by a factor of roughly three. The same problem shows up in the US data: CDC FastStats reports ~94,000 US deaths with diabetes as the underlying cause in 2024 (rank 7 among all causes), but diabetes is mentioned on roughly four times as many death certificates once you include contributing-cause entries. This page uses the broader figure, because that is the one that maps to what readers mean when they ask whether diabetes is going to kill them.
Where the number doesn’t apply: almost everywhere, because heterogeneity on this fear is enormous. Several Pacific Island nations — Marshall Islands, Kiribati, Tuvalu, Nauru — have adult diabetes prevalence above 25%, the highest rates anywhere on Earth, driven by a combination of genetic susceptibility and a rapid mid-century dietary transition from traditional foods to imported processed staples. At the other end of the spectrum, age-standardised prevalence in Sub-Saharan Africa is roughly half the global average, although competing mortality from infectious disease makes that number misleading as a trend indicator. Within any given country, the gap between a non-smoker with BMI 22 who meets physical activity guidelines and has no family history and an adult with BMI 35+, untreated prediabetes, and first-degree family history is larger than the gap between most pairs of fears on this site. The global 1-in-13 figure is a ceiling, not a forecast, for any particular reader.
関連する豆知識
2型糖尿病とアルツハイマーはどちらも主要死因で、生活習慣と強く関連し、緩慢に進行するため緊急性が生まれない。徐々に殺す脅威は恐怖反応を引き起こさない。
根拠台帳
以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。
4/5 件の出典が引用元と一字一句一致することを独立して検証済み
-
[1] International Diabetes Federation (Sun et al., Diabetes Research and Clinical Practice) — IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 検証済み
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045- 統計値
Global diabetes prevalence in 20-79 year olds in 2021 was 10.5% (536.6 million people), projected to rise to 12.2% (783.2 million) in 2045- 抜粋
“"The global diabetes prevalence in 20-79 year olds in 2021 was estimated to be 10.5% (536.6 million people), rising to 12.2% (783.2 million) in 2045. [...] Prevalence [in 2021] was estimated to be higher in urban (12.1%) than rural (8.3%) areas, and in high-income (11.1%) compared to low-income countries (5.5%). The greatest relative increase in the prevalence of diabetes between 2021 and 2045 is expected to occur in middle-income countries (21.1%)." ”
- 出典データ
- 2022-01-01
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- IDF’s 10th edition Atlas reports ~6.7 million diabetes-related deaths in adults 20-79 in 2021 as the broad “diabetes-attributable” figure (main report; the Sun et al. abstract itself covers prevalence not mortality). The 6.7M number is used as the numerator for the normalized rate: 6.7M / ~5.5B global adults ≈ 1.22 per 1,000 adults/year, compounded over 60 adult years → ~7%, adjusted to 7.5% for the age-concentration of diabetes mortality. IDF 536.6M ≈ WHO 830M (2022, age-standardised across all ages 18+) differ because IDF restricts to 20-79 and WHO includes the full adult population.
- 独立性
- IDF Atlas estimates and GBD 2021 diabetes estimates share substantial upstream data (national surveys, registry data, verbal autopsy studies) but use different modelling pipelines and are published separately; treat as partially but not fully independent of the Lancet GBD source below.
-
[2] World Health Organization — Diabetes — fact sheet 検証済み
Diabetes — fact sheet- 統計値
830 million adults living with diabetes in 2022; 14% of adults aged 18+; 1.6 million direct diabetes deaths in 2021 plus 530,000 diabetes-attributable kidney disease deaths; ~11% of cardiovascular deaths caused by high blood glucose; >95% of cases are type 2- 抜粋
“"In 2022, 14% of adults aged 18 years and older were living with diabetes, an increase from 7% in 1990. [...] More than 95% of people with diabetes have type 2 diabetes. [...] In 2021, diabetes and kidney disease due to diabetes caused over 2 million deaths. In addition, around 11% of cardiovascular deaths were caused by high blood glucose. [...] More than half of people living with diabetes did not take medication for their diabetes in 2022. Diabetes treatment was lowest in low- and middle-income countries." ”
- 出典データ
- 2024-11-14
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- WHO’s narrower underlying-cause count (1.6M direct diabetes deaths + 0.53M diabetes-attributable kidney disease deaths = ~2.1M) plus ~11% of the ~19.8M annual global CVD deaths (≈ 2.2M) gives ~4.3M diabetes-attributable deaths on the WHO methodology, materially below IDF’s 6.7M. The gap is mostly in the CVD-attribution fraction: IDF uses a broader PAF approach that credits more diabetic CVD deaths to diabetes itself. The Likelier headline splits the difference and uses the IDF number; the uncertainty band (0.05-0.12) covers both methodologies. Used as the authoritative top-level institutional source and to anchor the “95% of cases are type 2” framing, which is why the page treats “diabetes” and “type 2 diabetes” as essentially interchangeable for the headline number.
- 独立性
- WHO diabetes fact sheet draws on WHO Global Health Estimates, which in turn uses IHME GBD inputs; partially dependent on the Lancet GBD source but methodologically distinct in how it allocates CVD deaths to diabetes.
-
[3] GBD 2021 Diabetes Collaborators (The Lancet) — Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 検証済み
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021- 統計値
529 million people living with diabetes in 2021 (95% UI 500-564); type 2 diabetes accounts for 96.0% of cases and 95.4% of diabetes DALYs; global age-standardised prevalence 6.1%; highest regional rates in Oceania (12.3%) and North Africa/Middle East (9.3%); 1.31 billion projected by 2050- 抜粋
“"In 2021, there were 529 million (95% uncertainty interval [UI] 500-564) people living with diabetes worldwide. The global age-standardised total diabetes prevalence was 6·1% (5·8-6·5). [...] Type 2 diabetes [...] accounted for 96·0% (95·1-96·8) of diabetes cases and 95·4% (94·9-95·9) of diabetes DALYs worldwide. [...] The highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7-9·9]) and, at the regional level, in Oceania (12·3% [11·5-13·0]). [...] 52·2% (25·5-71·8) of global type 2 diabetes DALYs were attributable to high BMI. [...] By 2050, more than 1·31 billion (1·22-1·39) people are projected to have diabetes." ”
- 出典データ
- 2023-07-15
- アクセス日
- 2026-04-11 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- GBD 2021 gives a total-diabetes count (529M) about 1.5% below IDF (536.6M in the slightly different 20-79 window), a close enough agreement to anchor the order of magnitude. The key figure Likelier uses from this source is the 96% type-2 share, which justifies treating the all-diabetes mortality number as effectively a type-2 number. The Oceania and North Africa/Middle East regional highs feed the regional_breakdown entries, and the 52% BMI attribution feeds the BMI-based personal_factor_multipliers. Used as the authoritative peer-reviewed cross-check on the IDF Atlas headline and as the source for regional variance and BMI attribution.
- 独立性
- GBD 2021 uses the IHME Cause of Death Ensemble model pipeline, which is methodologically distinct from IDF’s Atlas modelling but draws on overlapping upstream vital registration data; partially dependent.
-
[4] US Centers for Disease Control and Prevention / National Center for Health Statistics — Diabetes — FastStats
Diabetes — FastStats- 統計値
94,445 US deaths with diabetes as underlying cause (2024); 27.8 deaths per 100,000; diabetes is the 7th-ranked cause of death in the US- 抜粋
“"Number of deaths: 94,445. Deaths per 100,000 population: 27.8. Cause of death rank: 7. [...] Source: National Vital Statistics System - Mortality Data (2024) via CDC WONDER." ”
- 出典データ
- 2026-02-20
- アクセス日
- 2026-04-11 · アーカイブ版
- 計算過程
- ~94,400 US underlying-cause deaths across ~260M US adults ≈ 0.36 per 1,000 adults/year. Compounded over 60 adult years: 1 - (1 - 3.6e-4)^60 ≈ 0.021, a US-only figure of ~2.1% on the strict underlying-cause definition. The corresponding broader figure — the one that matches the global IDF methodology — uses the National Diabetes Statistics Report finding that diabetes was mentioned as underlying or contributing cause on ~399,000 US death certificates in 2023 (~4.2x the underlying-cause count), implying a lifetime figure closer to 0.09 for US adults. That is what the US row in regional_breakdown reflects. Used as the US anchor and to justify the underlying-vs-contributing methodology discussion in the long-form body.
- 独立性
- CDC FastStats draws from the NCHS NVSS death-certificate pipeline, which also feeds into WHO Global Health Estimates and IHME GBD upstream. Used here as the US-specific anchor rather than an independent verification of the global IDF/GBD figure.
-
[5] Lincoff et al., New England Journal of Medicine — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) 検証済み
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial)- 統計値
Semaglutide 2.4mg reduced major adverse cardiovascular events by ~20% (hazard ratio 0.80, 95% CI 0.72-0.90) vs placebo in 17,604 overweight/obese adults aged 45+ with established cardiovascular disease and without diabetes; MACE occurred in 6.5% vs 8.0%- 抜粋
“"A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001)." ”
- 出典データ
- 2023-12-14
- アクセス日
- 2026-06-14 · アーカイブ版
- 検証
- グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
- 計算過程
- SELECT did not estimate diabetes mortality; it is used here solely to source the semaglutide (GLP-1 receptor agonist) protective personal_factor_multiplier of 0.80. The hazard ratio of 0.80 for major adverse cardiovascular events maps directly to a multiplier of 0.80 against the cardiovascular component of diabetes-related death, which is the dominant component in this entry's broad IDF "diabetes-attributable" headline. The trial enrolled patients without diabetes, so the cardiovascular benefit is established beyond the diabetic population; in type 2 diabetes specifically the effect direction is consistent with earlier GLP-1 RA cardiovascular-outcome trials. No change is made to the headline lifetime figure on the basis of this source.
- 独立性
- Industry-sponsored (Novo Nordisk) randomised controlled trial, independent of the IDF Atlas, WHO, GBD, and CDC mortality-surveillance sources above; used only as the basis for the GLP-1 RA protective multiplier, not as a cross-check on the headline.